ProShare Advisors
ICVX

ProShare Advisors’s Icosavax, Inc. Common Stock ICVX Stock Holding History

ProShare Advisors’s Portfolio ICVX Stock Details ICVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,767
Closed -$201K – 2327
2021
Q4 		$201K Buy
+8,767
New +$226K ﹤0.01% 2031

Other funds holding ICVX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ProShare Advisors's ICVX Position: Q1 2022 in Review

ProShare Advisors sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2022, closing a stake of 8,767 shares — an estimated $201K sold.

ProShare Advisors first reported a position in ICVX in Q4 2021 and held it in 1 quarter. The position peaked at $201K in Q4 2021. 65 funds tracked by Wall St. Rank hold ICVX as of Q1 2022.

  • ProShare Advisors reported no remaining Icosavax, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 8,767 Icosavax, Inc. Common Stock shares in Q1 2022, an estimated $201K.
  • ProShare Advisors first reported a position in Icosavax, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • ProShare Advisors's Icosavax, Inc. Common Stock position peaked at $201K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.